Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07235059 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
A Phase 1 study of Chronic Kidney Disease, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
- 2
- Study locations
NCT07235059: Recruiting Phase 1 study of Chronic Kidney Disease, sponsored by Novartis Pharmaceuticals.
NCT07235059 is a Phase 1 study of Chronic Kidney Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 112 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07235059, a Phase 1 study of Chronic Kidney Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.
Primary Outcome
Incidence and severity of AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG OJR520
Study Locations (2)
Florida
- Quotient Sciences Sea View - Miami
Other
- Novartis Investigative Site - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2025-11-20 |
| Est. Completion | 2027-07-19 |
| Phase | Phase 1 |
What NCT07235059 shows while recruiting
NCT07235059 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07235059 reports a single indexed study location in Florida, Other.
Frequently Asked Questions
What is clinical trial NCT07235059 about?
NCT07235059 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease". The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.
What is the current status of trial NCT07235059?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2025-11-20. Estimated completion is 2027-07-19.
What conditions does trial NCT07235059 study?
This clinical trial studies the following conditions: Chronic Kidney Disease.
What interventions are being tested in trial NCT07235059?
The interventions under investigation include: Placebo (OTHER), OJR520 (DRUG).
Who is sponsoring clinical trial NCT07235059?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07235059 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07235059's enrollment target sits among peer trials
112 54th of 101 higher than 48 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sympatholysis in Chronic Kidney Disease
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
RECRUITING · Phase 1
-
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
COMPLETED · Phase 1
-
A Trial of Doxycycline in Renal Disease
COMPLETED · Phase 1
-
A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease
COMPLETED · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI